Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.[2] Survanta is manufactured by Abbvie.

Clinical data
Trade namesSurvanta, Alveofact
Routes of
ATC code
  • none
Legal status
Legal status
  • UK: POM (Prescription only)
CAS Number
  • none
 NY (what is this?)  (verify)

Generic form

Beraksurf is generic form of Survanta (Beractant) which is manufacturing by Tekzima.


  1. Moya, F. R.; Gadzinowski, J.; Bancalari, E.; Salinas, V.; Kopelman, B.; Bancalari, A.; Kornacka, M. K.; Merritt, T. A.; Segal, R.; Schaber, C. J.; Tsai, H.; Massaro, J.; d'Agostino, R. (1 April 2005). "A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants". Pediatrics. 115 (4): 1018–1029. doi:10.1542/peds.2004-2183.
  2. Lotze, Andrea; Mitchell, Brian R.; Bulas, Dorothy I.; Zola, Elizabeth M.; Shalwitz, Robert A.; Gunkel, J.Harry (January 1998). "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure". The Journal of Pediatrics. 132 (1): 40–47. doi:10.1016/S0022-3476(98)70482-2.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.